MHRA approves Moderna鈥檚 adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5
皇冠体育app vaccine was approved after it was found to meet the MHRA鈥檚 standards of safety, quality and effectiveness.
An adapted COVID-19 vaccine from Moderna (Spikevax) that targets the Omicron XBB 1.5 subvariant, has today been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator鈥檚 standards of safety, quality and effectiveness.
皇冠体育app vaccine has been approved for use in individuals from 6 months of age.
皇冠体育app adapted vaccine works in the same way as the original vaccine by causing the immune system (the body鈥檚 natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19. All approved adapted COVID-19 vaccines help to improve the protection obtained from earlier doses of the vaccine and help give longer-term protection against getting seriously ill from COVID-19.
Further information:
- This new line extension was approved via the聽National licensing route. This marketing authorisation has been endorsed by the government鈥檚 independent Commission on Human Medicines after review of the data submitted on the quality, safety and effectiveness of the vaccine.
- More information can be found in the vaccine decision page on mhra.gov.uk
- 皇冠体育app Public Assessment Report will be published shortly.